MORSAL MOHAMMADI: Open Payments
NPI 1407512205 · SUMMIT, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,281 in 55 payments from 34 companies in 2025. Trend: 2023 $733 · 2024 $1,297 · 2025 $1,281
Food & beverage: $1,113Education: $168
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 2 | $121 |
| Aveo Pharmaceuticals, Inc. | 2 | $105 |
| ABBVIE INC. | 6 | $100 |
| SEAGEN INC. | 1 | $93 |
| PFIZER INC. | 4 | $69 |
| Novartis Pharmaceuticals Corporation | 3 | $66 |
| Genentech USA, Inc. | 3 | $59 |
| ADC THERAPEUTICS AMERICA, INC. | 3 | $59 |
| Janssen Biotech, Inc. | 2 | $42 |
| Genmab U.S., Inc. | 2 | $42 |
Products named: FOTIVDA, REBLOZYL, ZYNLONTA, PADCEV, Fabhalta, LYNPARZA, Tecentriq, EPKINLY.
Industry payments across NJ — which companies pay providers there.
